Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: nowadays the use of electroconvulsive therapy (ECT) has increased as a therapeutic alternative in several pathologies. The use of modified ECT helps reduce the physiological effects and adverse effects of the treatment; the objective of this study is to determine the safety of using rocuronium in electroconvulsive therapy. Materials and methods: a prospective study of a series of cases in which involved 47 electroconvulsive therapy was made, rocuronium was used as neuromuscular relaxant, in a dose of 0.3 mg / kg, average time to perform the electrical discharge was 5 minutes. Neostigmine and atropine was administered as reversal agent of paralysis. Results: the analysis of cases gave descriptive results, the average of TOF ratio obtained after 20 minutes of use of neostigmine and atropine was 88.7%, which does not ensure a return of spontaneous ventilation. Conclusions: the use of rocuronium in ECT is safe, provided that it is used with Sugammadex; this ensures reliable reversal of neuromuscular blockade and minimize potential adverse effects of non-depolarizing neuromuscular blockers.
Scot AIF. The ECT Handbook, 2nd Edn. Glasgow: The Royal College of Psychiatrists, 2005. American Psychiatric Association. The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging, 2nd edn. Washington DC: American Psychiatric Press, 2001
Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol 2008; 21: 3–11
Ding Z and White PF. Anesthesia for electroconvulsive therapy. Anesth Analg 2002; 94: 1351–1364
Vishal Uppal. Anaesthesia for electroconvulsive therapy. Continuing Education in Anaesthesia, Critical Care & Pain | Volume 10 Number 6 2010 192-196
Turkkal DC, Gokmen N, Yildiz A, Iyilikci L, Gokel E, Sagduyu K, Gunerli A. A cross-over, postelectroconvulsive therapy comparison of clinical recovery from rocuronium versus succinylcholine. J Clin Anesth 2008; 20: 589–93
Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, Nisman M. Intraoperative acceleromyographic monitoring reduces the risk of residual neu romuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109: 389 98
Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96: 36–43
Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107: 130–7
Miller RD, Van Nyhuis LS, Eger EI 2nd, Vitez TS, Way WL. Comparative times to peak effect and durations of action of neostigmine and pyridostigmine. Anesthesiology 1974; 41: 27–33
Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009; 103: 115–29. 122
Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006; 97: 123–6
Kopman AF. Sugammadex dose requirements at posttetanic counts of 1 to 2: cost implications. Anesth Analg 2010; 110: 1753–4
Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology 2010; 113: 1054–60
Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth 2010; 105: 568–75
Paton F, Paulden M, Chambers D, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth 2010; 105: 558–67
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.